Profusa to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
Profusa (NASDAQ: PFSA), a commercial stage digital health company focused on continuous biochemistry monitoring technology, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Ben Hwang, Ph.D., will deliver a corporate overview at the event, which takes place September 8-10, 2025 at the Lotte New York Palace Hotel.
The presentation will be available on demand to registered conference attendees starting September 5, 2025, at 7:00 AM ET. Investors can register for the conference and request one-on-one meetings through the conference website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PFSA declined 5.00%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.0% during that session. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $689K from the company's valuation, bringing the market cap to $13M at that time.
Data tracked by StockTitan Argus on the day of publication.
Berkeley, Calif, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces that Ben Hwang, Ph.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.
Dr. Hwang’s presentation will be available on demand beginning Friday, September 5 at 7:00am ET for registered investors of the conference. To request a one-on-one meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia. For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including risks regarding the highly volatile nature of the price of Bitcoin and other cryptocurrencies, as well as the risk that the Company's stock price may be highly correlated to the price of the digital assets that it holds. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in our Form S-1 Registration Statement (Registration No. 333-289461) filed with the SEC on August 11, 2025, and described in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts email: info@coreir.com
Phone: 1 (212) 655-0924
FAQ
When is Profusa (PFSA) presenting at the H.C. Wainwright Conference 2025?
Who will be presenting for Profusa at the H.C. Wainwright Conference?
Where is the H.C. Wainwright Global Investment Conference 2025 being held?
How can investors access Profusa's presentation at the H.C. Wainwright Conference?
